Immunovant Inc (IMVT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immunovant Inc (IMVT) has a cash flow conversion efficiency ratio of -0.094x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-92.33 Million) by net assets ($986.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See IMVT equity financing ratio to measure how much of total assets are equity-financed.
Immunovant Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Immunovant Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Immunovant Inc to evaluate the quality of earnings relative to operating cash generation.
Immunovant Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunovant Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Starwood Property Trust Inc
NYSE:STWD
|
0.045x |
|
CICT Mobile Communication Technology Co. Ltd. A
SHG:688387
|
N/A |
|
Reinet Investments S.C.A
AS:REINA
|
0.010x |
|
Flagstar Financial, Inc.
NYSE:FLG
|
-0.016x |
|
ZALANDO SE UNSP.ADR /2
F:ZAL1
|
N/A |
|
Soochow Securities Co Ltd
SHG:601555
|
0.336x |
|
Sam Yang Foods
KO:003230
|
0.052x |
|
SHISEIDO CO. ADR
F:SHDA
|
0.045x |
Annual Cash Flow Conversion Efficiency for Immunovant Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Immunovant Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Immunovant Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $707.45 Million | $-375.87 Million | -0.531x | -53.21% |
| 2024-03-31 | $617.76 Million | $-214.23 Million | -0.347x | +33.20% |
| 2023-03-31 | $362.49 Million | $-188.19 Million | -0.519x | -129.87% |
| 2022-03-31 | $469.82 Million | $-106.11 Million | -0.226x | -6.11% |
| 2021-03-31 | $391.48 Million | $-83.33 Million | -0.213x | +62.47% |
| 2020-03-31 | $94.07 Million | $-53.36 Million | -0.567x | +99.95% |
| 2019-03-31 | $24.55K | $-28.55 Million | -1162.716x | -1456.43% |
| 2018-03-31 | $-1.50 Million | $-128.30 Million | 85.719x | -- |
About Immunovant Inc
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating p… Read more